Weekly Chemotherapy for Advanced Breast Cancer
Author Information
Author(s): J.S. Cebon, J.F. Bishop, V. Harvey, B. Mason, P.N. Jeal
Primary Institution: Peter MacCallum Cancer Institute
Hypothesis
Can a dose-intense regimen of CMFVP be delivered to previously untreated outpatients with advanced breast cancer?
Conclusion
The weekly CMFVP regimen could not be effectively delivered to previously untreated outpatients due to significant toxicity and treatment delays.
Supporting Evidence
- 53% of evaluable patients had a complete or partial response.
- 62% of patients experienced grade 3 or 4 neutropenia.
- Median survival for all patients was 31 weeks.
Takeaway
Doctors tried a new way to give chemotherapy to breast cancer patients every week, but it made many patients too sick to continue.
Methodology
Patients received a combination of chemotherapy drugs weekly and were monitored for response and toxicity.
Limitations
The study had a small sample size and high rates of treatment delays and toxicity.
Participant Demographics
Median age was 55 years, with a range from 31 to 79; most had not received prior chemotherapy.
Want to read the original?
Access the complete publication on the publisher's website